Results 191 to 200 of about 618,319 (304)
CD93—An emerging vascular target in cancer therapy
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira +3 more
wiley +1 more source
Silver Nanoparticles Attenuate Histamine-Induced Pruritus via Modulation of the Nitric Oxide/iNOS Signaling Pathway in Mice. [PDF]
Bayan AM, Khan MI.
europepmc +1 more source
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov +2 more
wiley +1 more source
Is histamine intolerance a treatable subtype of fibromyalgia? evidence and clinical implications-narrative review. [PDF]
Protásio Netto J +6 more
europepmc +1 more source
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli +6 more
wiley +1 more source
Atopic dermatitis: pathogenesis, immunology, microbiome, and salivary biomarkers. [PDF]
Abraityte S +3 more
europepmc +1 more source
Histamine in Diabetic Cardiovascular Complications. [PDF]
Hu S +5 more
europepmc +1 more source
Suicidality associated with betahistine: A rare case report and systematic review of histaminergic drug-induced depression. [PDF]
Tang J, Zeng Y, Jiang X.
europepmc +1 more source
Rebound Pruritus and Urticaria After Discontinuation of Chronic Antihistamine Use—A Scoping Review
Rebound pruritus and urticaria have been reported after discontinuation of chronic cetirizine or levocetirizine use only. Symptoms typically occur within 0.5–5 days after stopping therapy and appear more frequently reported in female patients. Re‐initiation of antihistamines is the most commonly effective management strategy, highlighting the need for ...
Jun Jie Benjamin Seng +2 more
wiley +1 more source

